Metraipolis › archive › dc_2cc57e990894

Efficacy and safety of Telitacicept in IgA nephropathy and its impact on urinary Gd-IgA1: insights from a real-world study — Europe PMC PMID:41909683

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41909683
DOI
10.3389/fimmu.2026.1694197
License (as archived)
solo-consultazione
Archived
2026-11-04T20:17:31.420Z
SHA-256 of the archived text
1b6752eb18257475ed1f6c36a420d02c325b184f5469f629ca0431556c03ec78
Stable URL of this page
https://metraipolis.com/documento/dc_2cc57e990894

How to cite

Efficacy and safety of Telitacicept in IgA nephropathy and its impact on urinary Gd-IgA1: insights from a real-world study — Europe PMC PMID:41909683 — Europe PMC (en), https://europepmc.org/article/MED/41909683 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2cc57e990894 (Metraipolis archive dc_2cc57e990894, sha256 1b6752eb18257475ed1f6c36a420d02c325b184f5469f629ca0431556c03ec78)
BibTeX
@misc{dc2cc57e990894,
  title = {Efficacy and safety of Telitacicept in IgA nephropathy and its impact on urinary Gd-IgA1: insights from a real-world study — Europe PMC PMID:41909683},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41909683},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2cc57e990894; sha256 1b6752eb18257475ed1f6c36a420d02c325b184f5469f629ca0431556c03ec78},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41909683. Agents can read the archived copy with the MCP tool read_document.